×
ProKidney EBIT 2021-2024 | PROK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ProKidney ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
ProKidney EBIT 2021-2024 | PROK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
ProKidney ebit from 2021 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$79.9B
Zoetis (ZTS)
$70.1B
Daiichi Sankyo, - (DSNKY)
$43.9B
Takeda Pharmaceutical (TAK)
$43.7B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.3B
Astellas Pharma (ALPMY)
$17.4B
United Therapeutics (UTHR)
$17B
Summit Therapeutics (SMMT)
$15.9B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.4B
Corcept Therapeutics (CORT)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Orion OYJ (ORINY)
$7.4B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Grifols, S.A (GRFS)
$5.1B
Ionis Pharmaceuticals (IONS)
$5B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4.2B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Hypermarcas (HYPMY)
$2.2B
Centessa Pharmaceuticals (CNTA)
$2.1B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Ardelyx (ARDX)
$1.5B